News Center
With the tenet of "Healthy China, Dedicated commitment", Linuo Pharmaceuticals increases cooperation and association with external scientific research institutes while innovating and developing independently.
26
2023
-
05
Linuo Pharmaceutical and Porton Pharmaceuticals signed a strategic cooperation agreement
Classification：
Corporate News
On May 25, the strategic cooperation signing ceremony between Chongqing Porton Pharmaceutical Co., Ltd. [hereinafter referred to as Porton Pharmaceutical] and Shandong Linuo Pharmaceutical Co., Ltd. [hereinafter referred to as Linuo Pharmaceutical] was held in Chongqing. Chongqing Porton Pharmaceutical Technology Co., Ltd. (stock code 300363) Wang Zhongneng, vice president and general manager of the preparation division, Jiang Hongsheng, director and general manager of Keyuan Pharmaceuticals, and general manager of Linuo Pharmaceuticals, attended the signing ceremony.
Porton Pharmaceuticals is a wholly-owned subsidiary of Chongqing Porton Pharmaceutical Technology Co., Ltd., which mainly focuses on the construction of preparation technology platforms and outsourced research and development and production (CDMO) services of preparations. Based on the group company's API CDMO platform and years of industry experience, it extends to provide global drug research and development institutions and pharmaceutical companies with customized preparation development and production services from preclinical to marketing stages, and integrates to provide efficient, high-quality and reliable one-stop A service platform for drug R&D and production.
Linuo Pharmaceutical is a modern, high-tech pharmaceutical company integrating R&D, production and sales of drugs for chronic diseases such as hypoglycemic, cardiovascular and psychiatric drugs. The company has advanced tablet, capsule, paste and spray production lines and supporting facilities, and the main raw materials come from the parent company Shandong Keyuan Pharmaceutical Co., Ltd. (stock code 301281)). Keyuan Pharmaceutical is a leading company in the domestic raw material medicine subdivision track. It has successively passed the official drug administration certification of many countries such as the EU EDQM certification, the US FDA certification, the Japanese PMDA certification, and the Korean KFDA certification, providing stable and high-quality raw materials for Linuo Pharmaceutical. Support and guarantee, give full play to the synergistic advantages of the integration of raw materials and preparations, and improve the market competitiveness of Linuo Pharmaceutical.
After exchanges, based on the principles of resource sharing, complementary advantages, equality and mutual benefit, the two parties signed a strategic cooperation agreement. In the future, the two parties will carry out strategic cooperation in the fields of new product research and development, technical transformation of mature products, API and preparation business development, and work together to achieve better development in the overall situation of high-quality development.
Wang Zhongneng, vice president of Chongqing Porton Pharmaceutical Technology Co., Ltd. and general manager of the preparation department, and Jiang Hongsheng, director and general manager of Keyuan Pharmaceuticals and general manager of Linuo Pharmaceuticals, signed the contract on behalf of the two parties.
Related news
ADD：#30766 Jingshidong Road, Linuo High-tech Park, Jinan, Shandong Province, P. R. China
